BRPI0511136A - formulações em pó para inalação contendo beta-agonistas enantiÈmeros puros - Google Patents

formulações em pó para inalação contendo beta-agonistas enantiÈmeros puros

Info

Publication number
BRPI0511136A
BRPI0511136A BRPI0511136-6A BRPI0511136A BRPI0511136A BR PI0511136 A BRPI0511136 A BR PI0511136A BR PI0511136 A BRPI0511136 A BR PI0511136A BR PI0511136 A BRPI0511136 A BR PI0511136A
Authority
BR
Brazil
Prior art keywords
formulations containing
powder formulations
containing pure
agonists
inhalation powder
Prior art date
Application number
BRPI0511136-6A
Other languages
English (en)
Inventor
Michael Trunk
Joerg Schiewe
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35058202&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0511136(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of BRPI0511136A publication Critical patent/BRPI0511136A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

FORMULAçõES EM Pó PARA INALAçãO CONTENDO BETA-AGONISTAS ENANTIóMEROS PUROS. A presente invenção refere-se a formulações em pó para inalação contendo compostos enantiómeros puros da fórmula geral (1) em que os radicais R¬ 1¬, R¬ 2¬, R¬ 3¬ e R¬ 4¬ podem possuir os significados mencionados nas reivindicações e na descrição, eventualmente em forma de seus sais de adição de ácido farmaceuticamente compatíveis, bem como eventualmente em combinação com uma substância auxiliar farmaceuticamente compatível, a processos para sua preparação e ao seu uso como medicamento, particularmente como medicamento para o tratamento de doenças do trato respiratório.
BRPI0511136-6A 2004-05-14 2005-05-11 formulações em pó para inalação contendo beta-agonistas enantiÈmeros puros BRPI0511136A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004024451A DE102004024451A1 (de) 2004-05-14 2004-05-14 Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten
PCT/EP2005/005078 WO2005110359A1 (de) 2004-05-14 2005-05-11 Pulverformulierungen für die inhalation, die enantiomerenreine betaagonisten enthalten

Publications (1)

Publication Number Publication Date
BRPI0511136A true BRPI0511136A (pt) 2007-11-27

Family

ID=35058202

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511136-6A BRPI0511136A (pt) 2004-05-14 2005-05-11 formulações em pó para inalação contendo beta-agonistas enantiÈmeros puros

Country Status (24)

Country Link
EP (1) EP1809236B1 (pt)
JP (1) JP4891899B2 (pt)
KR (1) KR101270449B1 (pt)
CN (1) CN1984638A (pt)
AR (1) AR048899A1 (pt)
AU (1) AU2005244424B2 (pt)
BR (1) BRPI0511136A (pt)
CA (1) CA2565915C (pt)
DE (1) DE102004024451A1 (pt)
DK (1) DK1809236T3 (pt)
EA (1) EA012582B1 (pt)
ES (1) ES2401786T3 (pt)
IL (1) IL179215A (pt)
MX (1) MXPA06013221A (pt)
MY (1) MY145838A (pt)
NO (1) NO20065078L (pt)
PE (1) PE20060239A1 (pt)
PL (1) PL1809236T3 (pt)
SG (1) SG152258A1 (pt)
TW (1) TW200607508A (pt)
UA (1) UA86807C2 (pt)
UY (1) UY28896A1 (pt)
WO (1) WO2005110359A1 (pt)
ZA (1) ZA200607785B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004024452A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolformulierung für die Inhalation von Betaagonisten
EP1924553A1 (en) 2005-08-08 2008-05-28 Argenta Discovery Limited Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
ES2530991T3 (es) 2005-08-15 2015-03-09 Boehringer Ingelheim Int Procedimiento para la obtención de betamiméticos
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
PT2379507E (pt) 2008-12-30 2014-01-21 Pulmagen Therapeutics Inflammation Ltd Compostos de sulfonamida para o tratamento de desordens respiratórias
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
WO2014056840A1 (en) 2012-10-09 2014-04-17 Boehringer Ingelheim International Gmbh Beta-2-adrenoceptor agonist for the treatment of cough
EP3551187B1 (en) 2016-12-12 2021-02-17 Boehringer Ingelheim International GmbH Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with olodaterol

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3134590A1 (de) * 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
US4460581A (en) * 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
DE4318455A1 (de) 1993-06-03 1994-12-08 Boehringer Ingelheim Kg Kapselhalterung
IL152140A0 (en) * 2000-04-27 2003-05-29 Boehringer Ingelheim Pharma Novel, slow-acting betamimetics, a method for their production and their use as medicaments
GB0107106D0 (en) * 2001-03-21 2001-05-09 Boehringer Ingelheim Pharma Powder inhaler formulations
DE10141377A1 (de) * 2001-08-23 2003-03-13 Boehringer Ingelheim Pharma Aufstreuverfahren zur Herstellung von Pulverformulierungen
DE10212264A1 (de) 2002-03-20 2003-10-02 Boehringer Ingelheim Pharma Kristallines Mikronisat, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
UA80123C2 (en) 2002-04-09 2007-08-27 Boehringer Ingelheim Pharma Inhalation kit comprising inhalable powder of tiotropium
DE10253282A1 (de) * 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung

Also Published As

Publication number Publication date
EA200602016A1 (ru) 2007-06-29
MXPA06013221A (es) 2007-02-08
NO20065078L (no) 2006-11-28
ES2401786T3 (es) 2013-04-24
EA012582B1 (ru) 2009-10-30
CA2565915C (en) 2013-12-10
AR048899A1 (es) 2006-06-07
WO2005110359A1 (de) 2005-11-24
DK1809236T3 (da) 2013-02-11
ZA200607785B (en) 2008-07-30
CN1984638A (zh) 2007-06-20
KR20070016169A (ko) 2007-02-07
AU2005244424A1 (en) 2005-11-24
IL179215A (en) 2011-04-28
UY28896A1 (es) 2005-12-30
AU2005244424B2 (en) 2010-12-23
TW200607508A (en) 2006-03-01
EP1809236B1 (de) 2012-12-26
KR101270449B1 (ko) 2013-06-04
IL179215A0 (en) 2007-03-08
PL1809236T3 (pl) 2013-05-31
JP4891899B2 (ja) 2012-03-07
PE20060239A1 (es) 2006-03-27
EP1809236A1 (de) 2007-07-25
SG152258A1 (en) 2009-05-29
DE102004024451A1 (de) 2005-12-22
MY145838A (en) 2012-04-30
JP2007537195A (ja) 2007-12-20
UA86807C2 (ru) 2009-05-25
CA2565915A1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
BRPI0511136A (pt) formulações em pó para inalação contendo beta-agonistas enantiÈmeros puros
BRPI0510770A (pt) derivados de fluorglicosìdeos de pirazóis, medicamentos contendo esses compostos e seu uso
BRPI0718813B8 (pt) compostos derivados de 1,1-dióxido de 1,4-benzotiepina, medicamento que os compreendem e seus usos
BR0316605A (pt) Derivados de fluorglicosìdeos aromáticos, medicamentos contendo estes compostos e sua aplicação
BRPI0510080A (pt) combinações farmacêuticas contendo benzoxazina para tratar doenças respiratórias
ECSP055855A (es) Medicamentos en polvo para inhalación que contiene una sal de tiotropio y salmeterolxinafoato
BR0308274A (pt) Formulação de formoterol superfino
BRPI0610321B8 (pt) imidazoquinolinas como inibidores de lipídeo cinase, seu uso e seu processo de preparação, e preparação farmacêutica
BR112012031561A2 (pt) morfolino pirimidinas e seu uso em terapia.
BRPI0507966A (pt) uso de meloxicam para o tratamento de doenças respiratórias em porcos
BR112013032974A2 (pt) "derivados de 1,6-diazabiciclo [3,2,1]-octan-7-ona, seus usos, e composições farmacêuticas".
BRPI0316264B8 (pt) compostos, seu uso e formulação farmacêutica que os contém
BRPI0517803A (pt) pirazolpirimidinas 1,4-substituìdas como inibidores de cinase
BRPI0510084A (pt) benzoxazina para tratamento de doenças do trato respiratório
BR0317283A (pt) Derivados heterocìclicos de flúor-glicosìdeo, medicamentos contendo estes compostos e seu uso
BRPI0514091A (pt) 8-aminoalquiltioxantinas substituìdas, e seu uso como inibidores de dipepetidil peptidase iv
BR112014014341A2 (pt) Intermediário metilado, seu método de preparação e seus usos, e composição farmacêutica
BR112014012628A2 (pt) di-hidrodiazepinocarbazolonas tetra ou pentacíclicas fundidas como inibidoras de parp
BRPI0519351A2 (pt) medicamentos para o tratamento ou prevenÇço de doenÇas fibràticas
ECSP066544A (es) Nuevas sales de tiotropio, procedimientos para su preparación, así como formulaciones medicamentosas que las contienen
BRPI0308513B8 (pt) micronizado cristalino de brometo de tiotrópio, processo para sua preparação, uso do mesmo, composição farmacêutica, pó para inalação, processo para sua preparação e cápsula que o contém
UA110463C2 (ru) ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНІЛ)-5Н-ПІРИМІДО[5,4-d][2]БЕНЗАЗЕПІН-2-ІЛ]АМІНО}-2-МЕТОКСИБЕНЗОЙНОЇ КИСЛОТИ ДЛЯ ЛІКУВАННЯ РАКУ Й ІНШИХ ЗАХВОРЮВАНЬ І ПОРУШЕНЬ СТАНУ ЗДОРОВ'Я
BRPI0607258A2 (pt) uso, composto, bem como formulações farmacêuticas
BRPI0519854A2 (pt) 4- feniltetraidroquinolinas substituìdas, métodos para produzì-las, seu uso como fármaco, e fármaco contendo-as
UY27759A1 (es) Combinaciones de medicamentos que contienen compuestos heterocíclicos y un nuevo agente anticolinérgico.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.